Moderna cuts 2021 sales forecast for Covid-19 vaccine; shares tumble | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Wednesday
December 06, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
WEDNESDAY, DECEMBER 06, 2023
Moderna cuts 2021 sales forecast for Covid-19 vaccine; shares tumble

Coronavirus chronicle

Reuters
04 November, 2021, 06:25 pm
Last modified: 04 November, 2021, 06:27 pm

Related News

  • Moderna ties up with Immatics to boost cancer vaccine development
  • Moderna says updated Covid vaccine is effective against newer variant
  • Cancer and heart disease vaccines expected to be ready by 2030
  • Moderna reports positive results for RSV vaccine
  • Moderna refused China request to reveal vaccine technology: Financial Times

Moderna cuts 2021 sales forecast for Covid-19 vaccine; shares tumble

The company's sales target cut is in sharp contrast to that of larger rival Pfizer Inc, which earlier this week raised its sales forecast for its shot

Reuters
04 November, 2021, 06:25 pm
Last modified: 04 November, 2021, 06:27 pm
Coronavirus: On 16 November, 2020, US biotech company Moderna announced a vaccine against Covid-19 that is 94.5% effective. Montreal, 16 November, 2020/ Reuters
Coronavirus: On 16 November, 2020, US biotech company Moderna announced a vaccine against Covid-19 that is 94.5% effective. Montreal, 16 November, 2020/ Reuters

Moderna Inc on Thursday cut its 2021 sales forecast for its Covid-19 vaccine by as much as $5 billion, as it struggles to ramp up production of its two-dose inoculation, sending its shares down nearly 11% in premarket trading.

The company's sales target cut is in sharp contrast to that of larger rival Pfizer Inc, which earlier this week raised its sales forecast for its shot.

Moderna's deliveries have been uneven as the company and its contract manufacturers strive to expand production and bottling of the shots to meet unprecedented demand from countries.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The vaccine-maker said it was seeing a temporary impact from the expansion of bottling capacity, also known as fill/finish, and that longer lead times for international shipments would push some deliveries to early 2022.

Moderna said it was now expecting sales of between $15 billion and $18 billion from $20 billion estimated previously.

The cut in sales forecast was also due to the prioritization of deliveries to low-income countries.

Roughly 10% of the vaccine's total supply is expected to go to low-income nations, Chief Executive Officer Stéphane Bancel said.

Deliveries were pegged between 700 million and 800 million doses for the year. Moderna has said it expects to make 800 million to 1 billion doses in 2021.

The Covid-19 vaccine brought in sales of $4.8 billion in the third quarter. Analysts had expected sales of $5.86 billion, according to five analysts polled by Refinitiv.

Still, Moderna said its sales could be in the range of $17 billion to $22 billion next year as it signs deals with more countries for its vaccines and booster doses.

Top News / World+Biz / Global Economy

Moderna Covid-19 Vaccine / Moderna / Moderna Inc

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Representational image. Photo: Collected
    No tax on foreign loan interest till February: NBR
  • Law, Justice and Parliamentary Affairs Minister Anisul Huq. File photo: Collected
    From Tk6 lakh to Tk11 crore, law minister's cash balloons
  • Photo: Reuters
    Meta restricts record 2,270 contents in Bangladesh in Jan-Jun

MOST VIEWED

  • For the first time, Bangladesh seeks foreign loans to support Rohingyas
    For the first time, Bangladesh seeks foreign loans to support Rohingyas
  • Photo: Collected
    Indonesia volcano erupts, spews ash 3 km into sky
  • A screengrab of Shakib Al Hasan speaking at Magura Awami League office on Wednesday (28 November).
    Shakib's annual income Tk5.5cr, bank loan Tk32cr
  • Caption: Illustration: TBS
    Source tax on land registration cut again
  • Treasury bill interest rate tops 11%
    Treasury bill interest rate tops 11%
  • External trade through Islamic banks in decline
    External trade through Islamic banks in decline

Related News

  • Moderna ties up with Immatics to boost cancer vaccine development
  • Moderna says updated Covid vaccine is effective against newer variant
  • Cancer and heart disease vaccines expected to be ready by 2030
  • Moderna reports positive results for RSV vaccine
  • Moderna refused China request to reveal vaccine technology: Financial Times

Features

Ghulam Ali

Ghulam Ali: Voice that makes ghazals bloom

9h | Features
Exploring door designs: Redefining spaces and experiences

Exploring door designs: Redefining spaces and experiences

11h | Habitat
A brain drain query: Why do they leave?

A brain drain query: Why do they leave?

16h | Panorama
The school has been flooding since June 2007 and the water level is rising every year. PHOTO: COURTESY

Will Dubai pay heed to the suffering of Sultan Al Nahyan School students in Bangladesh?

16h | Panorama

More Videos from TBS

Will the United States - Israel attack Yemen?

Will the United States - Israel attack Yemen?

2h | TBS World
Venues revealed for 2024 Copa America

Venues revealed for 2024 Copa America

3h | TBS SPORTS
Keffiyeh, the traditional garment, became the national symbol of Palestine

Keffiyeh, the traditional garment, became the national symbol of Palestine

5h | TBS World
An Argentine night in club football

An Argentine night in club football

7h | TBS SPORTS
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net